Vimarsana
Biggest News Aggregation in the World

Page 2 - Optum Research Database News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Optum Research Database. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Optum Research Database Today - Breaking & Trending Today

Real-World mCSPC First-Line Treatment Intensification Remains Low - Vimarsana News

Real-World mCSPC First-Line Treatment Intensification Remains Low

Investigators probed use of standard-of-care first-line metastatic castration-sensitive prostate cancer (mCSPC) treatment intensification.

Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab - Vimarsana News

Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab

First-line pembrolizumab-axitinib leads to lower health care resource utilization than ipilimumab-nivolumab in metastatic renal cell carcinoma.

Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma - Vimarsana News

Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

Source: empr.com
Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma - Vimarsana News

Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma

Mepolizumab use reduced exacerbations and the use of oral corticosteroids in patients with both allergic and non-allergic asthma.

Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab - Vimarsana News

Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab

First-line pembrolizumab-axitinib leads to lower health care resource utilization than ipilimumab-nivolumab in metastatic renal cell carcinoma.